Skip to content

Sustained Attention Abilities in Schizophrenia

Sustained Attention Abilities, Attentional Resources and Cognitive Control Mechanisms in Schizophrenia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02388607
Acronym
ACCRAS
Enrollment
80
Registered
2015-03-17
Start date
2015-03-31
Completion date
2023-03-31
Last updated
2021-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenic Psychoses

Brief summary

Schizophrenia is a psychiatric pathology, which concerns around 1% of adult population. It is characterized by clinical symptoms combining positive and negative symptoms and thinking disorganization. Schizophrenia is also characterized by cognitive deficits, likely to play an important part in adaptation of these patients in their every-day life, and to affect their clinical symptomatology. Among them, there are deficits in sustained attention which are associated with a difficulty for these patients to maintain efficiently their cognitive activity on a source of stimulation or task. This basic attentional process is fundamental for the efficiency of the overall of cognitive processes, and so for all behaviors directed on an aim. The question of whether or not patients with schizophrenia have difficulty sustaining attention is of high relevance, in the sense that it could undermine performance on nearly any task and so provide a compelling causal explanation of many other impairments observed in these patients. Yet it has not been conclusively answered in over four decades of research. Consequently, the main objective of the protocol is to evaluate sustained attention abilities in schizophrenic patients and to better understand the specific functioning of cognitive and neural mechanisms underlying these abilities (attentional resources and cognitive control mechanisms).

Interventions

performance measurements

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* age between 18 and 60 years (include) * men or women volunteers, hospitalized or not * subject affiliated to an health insurance * subject having signed an informed consent (for patients): * presence of DSM-IV TR criteria for schizophrenia (American Psychiatric Association, 1994)

Exclusion criteria

* a major somatic disorder or non stabilized * medical history likely to affect cerebral anatomy or to be linked to an abnormality (neonatal distress, neurochirurgical intervention, neurological disorders, stroke attack) * any disorders involved in the use of a psycho-active substance (as defined by the DSM-IV) * sensory disabling impairments, and specifically visual acuity \< 8 * general anaesthesia during the 3 months before the study * pregnancy (declared by the subject) * persons in an emergency situation * persons deprived in any way of their liberty * persons in period of exclusion in an other protocol * use of psychotropic substance during the 3 weeks before the study * use of benzodiazepines

Design outcomes

Primary

MeasureTime frameDescription
Assess sustained attention span of patients with schizophreniatwo half-daysSubjects are involved in 4 different attentional tasks during which behavioral and electrophysiological measures are recorded in order to evaluate sustained attention abilities and the specific functioning of cognitive and neural mechanisms underlying these abilities in schizophrenic patients.

Secondary

MeasureTime frameDescription
Study the specific mechanisms underlying attention skills supported in schizophrenic patientstwo half-daysSubjects are involved in 4 different attentional tasks during which behavioral and electrophysiological measures are recorded in order to evaluate sustained attention abilities and the specific functioning of cognitive and neural mechanisms underlying these abilities in schizophrenic patients.

Countries

France

Contacts

Primary ContactDimitri Sanchez
drci@chru-strasbourg.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026